Grape seed proanthocyanidin extract inhibits ferroptosis by activating Nrf2/HO-1 and protects against diabetic kidney

Tingting Li1,2, Hao Wang2, Baolei Chang2

  • 1College of Public Health, Xinjiang Medical University, Urumqi, China.

Plos One
|December 11, 2025
PubMed
Abstract

Insights

Grape seed proanthocyanidin extract (GSPE) reduces kidney damage in diabetic kidney disease (DKD) by inhibiting ferroptosis. This protective effect is mediated through the Nrf2/HO-1 pathway, highlighting GSPE as a potential therapeutic agent for DKD.

Area of Science:

  • Nephrology
  • Cell Biology
  • Pharmacology

Background:

  • Diabetic kidney disease (DKD) is characterized by renal dysfunction due to tubular injury.
  • Ferroptosis, a distinct cell death pathway, is implicated in DKD-related tubular injury.
  • The Nuclear factor erythroid-2 related factor 2/heme oxygenase 1 (Nrf2/HO-1) pathway plays a key role in regulating ferroptosis.

Purpose of the Study:

  • To investigate the protective effects of Grape seed proanthocyanidin extract (GSPE) against ferroptosis in diabetic kidney disease (DKD).
  • To elucidate the role of the Nrf2/HO-1 pathway in GSPE's protective mechanism against DKD.

Main Methods:

  • Established streptozotocin (STZ)-induced diabetic rat models and high glucose-cultured HK2 cells.
  • Assessed renal morphology, Fe2+ levels, reactive oxygen species (ROS), and apoptosis.
  • Utilized western blot to detect key proteins (TfR1, ACSL4, GPX4, Nrf2, HO-1) and performed Nrf2 knockdown experiments.

Main Results:

  • GSPE treatment significantly alleviated renal impairment, oxidative stress, and ferroptosis in DKD models.
  • Ferrostatin-1 (Fer-1) enhanced GSPE's anti-ferroptotic effects.
  • Downregulation of Nrf2 expression diminished the anti-ferroptotic efficacy of GSPE in HK2 cells.

Conclusions:

  • GSPE effectively reduces ferroptosis in DKD by modulating the Nrf2/HO-1 pathway.
  • These findings highlight ferroptosis as a significant factor in DKD pathogenesis.
  • GSPE demonstrates potential as a therapeutic strategy for managing DKD.